Smoking and Kidney Functions

Ahmet Dönder 1 * , Ragıp Balahoroğlu 1, Haluk Dülger 2, Mehmet Ramazan Sekeroğlu 1
More Detail
1 Yüzüncü Yıl Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Van, Türkiye
2 Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Konya, Türkiye
* Corresponding Author
EUR J BASIC MED SCI, Volume 4, Issue 1, pp. 16-21. https://doi.org/10.15197/sabad.2.4.04
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

There exist various harmful substances in cigarette and in its smoke. Nicotine, taken as a result of active and second hand smoking, turns into “cotinine” with metabolite. Cigarette is known to have toxic effects on peripherical nervous system, cardiovasvcular system and endocrin system. Besides, it causes lung, larynx, kidney and urinary bladder and breast cancer. Some mechanisms of cigarette have been reported to cause renal damage. It increases blood pressure leading to the activation of acute sympatethic system. It causes the formation of oxidative stress. It brings about renal dysfunction affecting the structure and functions of kidney. It may cause renal dysfunction both in healthy individuals and in patients with hypertension and diabetes. As a result of this review, the active and passive smoking are discussed in a negative impact on renal function.

CITATION

Dönder A, Balahoroğlu R, Dülger H, Sekeroğlu MR. Smoking and Kidney Functions. Eur J Basic Med Sci. 2014;4(1):16-21. https://doi.org/10.15197/sabad.2.4.04

REFERENCES

  • Beyer J, Waverly I. Tobacco control policy, strategies, successes and setbacks. The World Bank 2003; 1-12.
  • Pekşen Y. Sigara içiminin nedenleri, epidemiyolojisi, pasif içicilik. In: Tür A (ed). Sigaranın sağlığa etkileri ve bırakma yöntemleri. Logos 1995; 1-28.
  • Roszczenko A, Galazyn-Sidorczuk M, Brzoska MM, Moniuszko-Jakoniuk J, Zwierz K. Chosen parameters of the kidney function in smokers in relation to the exposure to cadmium. Przegl Lek 2004; 6: 348-50.
  • Cooper RG. Effect of tobacco smoking on renal function. Indian J Med Res 2006; 124: 261-8.
  • Hansen HP, Rossing K, Jacobsen P, Jensen BR, Parving HH. The acute effect of smoking on systemic haemodynamics, kidney and endothelial functions in insulin-dependent diabetic patients with microalbuminuria. Scand J Clin Lab Invest 1996; 56: 393-9.
  • Orth SR. Smoking-a renal risk factor. Nephron 2000; 86: 12–26.
  • Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients-absence of evidence or evidence of absence? Clin J Am Soc Nephrol 2008; 3: 226-36.
  • Aronow WS, Dendinger J, Rokaw SN. Heart rate and carbon monoxide level after smoking high-, low-, and nonnicotine cigarettes A study in male patients with angina pectoris. Ann Intern Med 1971; 74: 697-702.
  • Amann K, Rump LC, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469-78.
  • Orth SR, Viedt C, Ritz E. Adverse effects of smoking in the renal patient. Tohoku J Ex Med 2001; 194: 1-15.
  • Grassi G, Seravalle G, Calhoun DA, et al. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation 1994; 90: 248-53.
  • Haass M, Kübler W. Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther 1997; 10: 657-65.
  • Hansen KW, Pedersen MM, Christiansen JS, Mogensen CE. Night blood pressure and cigarette smoking: disparate association in healthy subjects and diabetic patients. Blood Press 1994; 3: 381-8.
  • Noronha-Dutra AA, Epperlein MM, Woolf N. Effect of cigarette smoking on cultured human endothelial cells. Cardiovasc Res 1993; 27: 774-8.
  • Mimic-Oka J, Simic T, Djukanovic L, Reljic Z, Davicevic Z. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol 1999; 51: 233-41.
  • Brischetto CS, Connor WE, Connor SL, Matarazzo JD. Plasma lipid and lipoprotein profiles of cigarette smokers from randomly selected families: enhancement of hyperlipidemia and depression of high-density lipoprotein. Am J Cardiol 1983; 1;52: 675-80.
  • Parthasarathy S, Steinberg D, Witztum JL. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med 1992; 43: 219-25.
  • Matsumoto N, Ishimura E, Taniwaki H, et al. Smoking and proteinuria impair vasodilatory response of intrarenal arteries to nitroglycerine in patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation 2002; 17: 608-13.
  • Emori T, Hirata Y, Ohta K, Shichiri M, Marumo F. Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells. Biochem Biophys Res Commun 1989; 14; 160:93-100.
  • Nasr MA, El-Gowilly SM, El-Mas MM . Comparable renovascular protective effects of moxonidine and simvastatin in rats exposed to cigarette smoke. Vascul Pharmacol 2010; 53: 53-60.
  • Schmidt A, Bunte A, Buddecke E. Proliferation-dependent changes of proteoglycan metabolism in arterial smooth muscle cells. Biol Chem Hoppe Seyler 1987; 368: 277-84.
  • Camejo G, Acquatella H, Lalaguna F . The interaction of low density lipoproteins with arterial proteoglycans. An additional risk factor? Atherosclerosis 1980; 36: 55-65.
  • Massy ZA, Keane WF. Pathogenesis of atherosclerosis. Semin Nephrol 1996; 16: 12-20.
  • Humphries DE, Lee SL, Fanburg BL, Silbert JE. Effects of hypoxia and hyperoxia on proteoglycan production by bovine pulmonary artery endothelial cells. J Cell Physiol 1986; 126: 249-53.
  • Gambaro G, Baggio B. Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol Dial Transplant 1996; 11: 762-4.
  • Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 1991; 31: 29-34.
  • Baylis C, Schmidt R. The aging glomerulus. Semin Nephrol 1996; 16: 265-76.
  • FeIs LM. Risk assesment of nephrotoxicity of cadmium. Ren Fail 1999; 21: 275-28157.
  • Janssen WM, Hillege H, Pinto-Sietsma SJ, Bak AA, De Zeeuw D, de Jong PE. Low levels of urinary albumin excretion are associated with cardiovascular risk factors in the general population Clin Chem Lab Med 2000; 38: 1107–10.
  • Halimi JM, Giraudeau B, Vol S, et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 2000; 58: 1285–92.
  • Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-8.
  • Dülger H, Dönder A, Şekeroğlu MR, Erkoç R, Özbay B. Investigation of the relationship between serum levels of cotinine and the renal function in active and passive smokers. Ren Fail 2011; 33: 475-9.
  • Lhotta K, Rumpelt HJ, Konig P, Mayer G, Kronenberg F. Cigarette smoking and vascular pathology in renal biopsies. Kidney Int 2001; 61: 648–54.
  • Dündar M, Kocak I, Culhacı N. Effects of long term passive smoking on the diameter of glomeruli in rats: histopathological evaluation. Nephrology 2004; 9: 53–7.
  • Obert DM, Hua P, Pilkertom ME, Feng W, Jaimes EA. Environmental tobacco smoke furthers progression of diabetic nephropathy. Am J Med Sci 2011; 341: 126-30.
  • Wachtell K, Olsen MH, Dahlof B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Life Study. J Hypertension 2002; 20: 405-12.
  • Mimran A, Ribstein J, Du Cailar G. Microalbuminuria in essential hypertension. Current Opinion in Nephrology and Hypertension 1999; 8: 59-363.
  • Hogan SL, Vupputuri S, Guo X, et al. Association of cigarette smoking with albuminuria in the United States: the third National Health and Nutrition Examination Survey. Ren Fail 2007; 29: 133-42.
  • Regalado M, Yang S, Wesson DE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 2000; 35: 687-94.
  • Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25: 587–94.
  • Christiansen JS. Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care 1978; 1: 146-9.
  • Telmer S, Christiansen JS, Andersen AR, Nerup J, Deckert T. Smoking habits and prevalence of clinical diabetic microangiopathy in insulin-dependent diabetics. Acta Med Scand 1984; 215: 63-8.
  • Orth SR, Ritz E. The renal risks of smoking: an update. Kidney Int 2002; 51: 1669-77.
  • Borch-Johnsen K, Nissen H, Henriksen E, et al. The natural history of insulin-dependent diabetes mellitus in Denmark: 1. Long-term survival with and without late diabetic complications. Diabet Med 1987; 4: 201-10.
  • Stengel B, Couchoud C, Cenee S, Hemon D. Age, blood pressure and smoking effects on chronic renal failure in primary glomerular nephropathies. Kidney Int 2000; 57: 2519-26.
  • Samuelsson O, Attman PO. Is smoking a risk factor for progression of chronic renal failure? Kidney Int 2000; 58: 2597.
  • Benck U, Clorius JH, Zuna I, Ritz E. Renal hemodynamic changes during smoking, Effects of adrenoreceptor blockade. Eur J Clin Invest 1999; 29: 1010-18.
  • Sung RS, Althoen M, Howell TA, Ojo AO, Merion RM. Excess risk of renal allograft loss associated with cigarette smoking. Transplantation 2001; 71: 1752-7.
  • Chase HP, Garg SK, Marshall G, et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991; 265: 614-7.
  • Gambaro G, Bax G, Fusaro M, et al. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes Nutr Metab 2001; 14: 337–42.